BiBB receives approval of two patents in Europe for EndoDrill
The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company") today announces that the European Patent Office (EPO) has finally approved two patent applications for EndoDrill®. The patents provide broad protection of the EndoDrill® system until 2038 and 2039, respectively.
The approvals relate to patent applications EP19780264.8 and EP18199230.6 from patent family 1 and follow previous Intention to Grants from the EPO announced in Q1 2023. The patents protect the EndoDrill® product series, the world's first market-cleared electric-driven biopsy instrument for endoscopy. BiBB also has three international patent applications for EndoDrill®, which has entered the national/regional phase.
EndoDrill® is in clinical phase and approaching commercialization. The product family is aimed at hospitals working with advanced ultrasound endoscopy (EUS/EBUS), to improve diagnostics in some of the most serious cancers, such as stomach, pancreas, liver, lung, and bladder cancer.
"Patent approvals in Europe come well timed ahead of our first launch activity with EndoDrill® GI in Oslo at the 6th Nordic EUS Meeting at the end of November. It will be the premiere of our new biopsy system at a congress and the fact that we have now received two patent approvals in Europe is a good foundation to stand on", says Fredrik Lindblad, CEO of BiBB.
About EndoDrill®
FDA-cleared EndoDrill® gives endoscopists increased opportunities to take high-quality coherent core biopsies in suspected tumors. An intact tissue sample contains more information, which can be crucial for accurate and complete diagnosis as well as the earliest possible start of treatment. The completed clinical pilot study with EndoDrill® GI (EDMX01) showed one hundred percent diagnostic accuracy when analyzing the samples.
EndoDrill® utilizes a patented electric-driven rotating needle cylinder that provides high-precision tissue samples of higher diagnostic quality than existing manually handled EUS biopsy instruments.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: [email protected]
Phone: +46 70 899 94 86
www.bibbinstruments.com
About BiBBInstruments AB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product series of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, e.g., in the stomach, pancreas, liver, lung, and bladder. The product portfolio targets the global market for ultrasound-guided (EUS/EBUS) biopsy instruments, which is the most advanced and fast-growing area of endoscopy. In 2023, EndoDrill® GI, BiBB's most important product variant, received market clearance from the US FDA as the first electric biopsy instrument for endoscopy in the US. The EndoDrill® system includes sterile disposable needle biopsy instruments with associated drive system (reusable part). The company was founded in 2013 by Dr Charles Walther, cancer researcher at Lund University and chief physician in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and BiBBInstrument's share (Ticker: BIBB) is listed on Spotlight Stock Market.
